roximately $17.3 million and $13.2 million, respectively. Management believes that the Company will continue to incur net losses and cash flow deficiencies from operating activities for the foreseeable future. Because it may take years to develop, test and obtain regulatory approval for a gene-based therapy product before it can be sold, the Company likely will continue to incur significant losses for the foreseeable future. Accordingly, it may never be profitable and, if it does become profitable, it may be unable to sustain profitability.

• In order to obtain the regulatory approvals necessary to commercialize its current or future product candidates, from time to time the Company will need to raise funds through public or private equity offerings, debt financings or additional corporate collaboration and licensing arrangements. Availability of financing depends upon a number of factors beyond the Company's control, including market conditions and interest rates. The Company does not know whether additional financing will be available when needed, or if available, will be on acceptable or favorable terms to it or its stockholders.

• The Company will need to conduct future clinical trials for treatment of Parkinson's disease using the Company's NLX technology. If the trials prove unsuccessful, future operations and the potential for profitability will be materially adversely affected and the business may not succeed.

• There is no assurance as to when, or if, the Company will be able to successfully complete the required preclinical testing of its gene therapy for the treatment of epilepsy to enable it to file an Investigational New Drug Application with the FDA for permission to begin a Phase I safety trial or that, if filed, such permission will be granted.

Other factors and assumptions not identified above could also cause the actual results to differ materially from those set forth in
'"/>


17-Oct-2006

Page: 1 2 3 4 5
Related biology news :

1. Successful development of prototype assays
2. Successful lung cancer surgery not enough to break nicotine dependence in many smokers
3. Successful transplantation from pig embryos to mice
4. Successful cell engineering may lead to mad cow prevention, say researchers
5. Successful test of single molecule switch opens the door to biomolecular electronics
6. Testosterone replacement therapy: How safe for aging men?
7. Progesterone therapy and preterm birth: More evidence helps identify women who can benefit
8. Aggressive therapy best for certain AML patients
9. Under magnetic force, nanoparticles may deliver gene therapy
10. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. Stem cell therapy rescues motor neurons in ALS model